Habitat Imaging of Tumors Enables High Confidence Sub-Regional Assessment of Response to Therapy

Habitat Imaging of Tumors Enables High Confidence Sub-Regional Assessment of Response to Therapy

Imaging biomarkers are used in therapy development to identify and quantify therapeutic response. In oncology, use of MRI, PET and other imaging methods can be complicated by spatially complex and heterogeneous tumor micro-environments, non-Gaussian data and small sample sizes. Linear Poisson Modell...

Full description

Saved in:
Bibliographic Details
Published in:Cancers Vol. 14; no. 9; p. 2159
Main Authors: Tar, Paul David, Thacker, Neil A, Babur, Muhammad, Lipowska-Bhalla, Grazyna, Cheung, Susan, Little, Ross A, Williams, Kaye J, O'Connor, James P B
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 26-04-2022
MDPI
Subjects:
Animal models
Biomarkers
Brain cancer
Cancer
Clinical trials
Colorectal cancer
Habitats
Histograms
Magnetic resonance imaging
Mathematical models
Medical imaging
Medical research
Radiation therapy
Tumors
Xenografts
cancer
diffusion weighted MRI
machine learning
imaging
modelling
statistics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imaging biomarkers are used in therapy development to identify and quantify therapeutic response. In oncology, use of MRI, PET and other imaging methods can be complicated by spatially complex and heterogeneous tumor micro-environments, non-Gaussian data and small sample sizes. Linear Poisson Modelling (LPM) enables analysis of complex data that is quantitative and can operate in small data domains. We performed experiments in 5 mouse models to evaluate the ability of LPM to identify responding tumor habitats across a range of radiation and targeted drug therapies. We tested if LPM could identify differential biological response rates. We calculated the theoretical sample size constraints for applying LPM to new data. We then performed a co-clinical trial using small data to test if LPM could detect multiple therapeutics with both improved power and reduced animal numbers compared to conventional -test approaches. Our data showed that LPM greatly increased the amount of information extracted from diffusion-weighted imaging, compared to cohort -tests. LPM distinguished biological response rates between Calu6 tumors treated with 3 different therapies and between Calu6 tumors and 4 other xenograft models treated with radiotherapy. A simulated co-clinical trial using real data detected high precision per-tumor treatment effects in as few as 3 mice per cohort, with -values as low as 1 in 10,000. These findings provide a route to simultaneously improve the information derived from preclinical imaging while reducing and refining the use of animals in cancer research.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14092159